OTCMKTS:PFSCF

ProMetic Life Sciences Stock Forecast, Price & News

$5.47
-0.20 (-3.58 %)
(As of 11/15/2019)
Add
Compare
Today's Range
$5.47
Now: $5.47▼
$5.47
50-Day Range
$5.47
MA: $5.47▼
$5.47
52-Week Range
$5.47
Now: $5.47▼
$352.00
Volume200 shs
Average Volume279 shs
Market Capitalization$127.45 million
P/E RatioN/A
Dividend YieldN/A
Beta2.46
Prometic Life Sciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs in the field of fibrosis and orphan diseases. Its product pipeline includes PBI-4050, an orally active lead drug candidate for fibrosis; plasminogen, a biopharmaceutical for the treatment of congenital plasminogen deficiency; and intravenous immunoglobulin, a preparation of antibodies purified from plasma donations from healthy individuals. The company was founded in 1992 and is based in Laval, Canada.
ProMetic Life Sciences logo

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:PFSCF
Previous SymbolNASDAQ:PFSCF
CUSIPN/A
CIKN/A
Webwww.prometic.com
Phone1-450-781-0115
Employees487
Year FoundedN/A

Debt

Debt-to-Equity RatioN/A
Current Ratio0.95
Quick Ratio0.71

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$36.55 million
Price / Sales3.49
Cash FlowN/A
Price / Cash FlowN/A
Book Value($67.63) per share
Price / Book-0.08

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-150,730,000.00
Net Margins-894.02%
Return on Equity-3,350.55%
Return on Assets-67.76%

Miscellaneous

Outstanding Shares23,313,000
Market Cap$127.45 million
Next Earnings DateN/A
OptionableNot Optionable

Headlines

Global Kidney Fibrosis Treatment Market Regional Trends & Growth Projections 2026
April 14, 2021 |  marketwatch.com
U.S Kidney/Renal Fibrosis Treatment Market Share Analysis Of Key Participants And Their Competitive Landscape up to 2027
April 14, 2021 |  marketwatch.com
Scleroderma Therapeutics Market Size to Record US$ 2.10 Bn through 2028 - MarketWatch
April 9, 2021 |  marketwatch.com
ProMetic Life Sciences (OTCMKTS:PFSCF) Stock Passes Below Fifty Day Moving Average of $5.47
April 3, 2021 |  americanbankingnews.com
ProMetic Life Sciences (OTCMKTS:PFSCF) Stock Price Down 3.6%
March 26, 2021 |  americanbankingnews.com
Liver Diseases Therapeutics Drugs Market Size 2021 by Consumption Volume, Average Price, Revenue, Market Share and Trend to 2025
February 2, 2021 |  marketwatch.com
Kidney Fibrosis Treatment Market 2021 Overview and Outlook – Merck and Co(US), Pfizer Inc(US), F. Hoffman-La Roche(Switzerland)
January 29, 2021 |  marketwatch.com
Idiopathic Pulmonary Fibrosis Market Global Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast 2020 to 2027
December 28, 2020 |  marketwatch.com
atai Life Sciences Appoints New Chief Financial Officer and Chief Medical Officer
December 16, 2020 |  markets.businessinsider.com
Prometic Life Sciences Inc Registered Shs hosts conference call for investors
November 7, 2020 |  markets.businessinsider.com
Liminal BioSciences Provides Update on Progress on BLA for Ryplazim®(plasminogen)
September 21, 2020 |  finance.yahoo.com
Prometic to Initiate PBI-4050 Pivotal Phase 3 Clinical Trial in Alström Syndrome
September 17, 2020 |  bloomberg.com
Liminal BioSciences to Present at The H.C. Wainwright 22nd Annual Global Investment Conference
September 9, 2020 |  finance.yahoo.com
Liver Diseases Treatment Market 2020 Disclosing Latest Trends and Advancement Outlook 2026
August 22, 2020 |  marketwatch.com
Idiopathic Pulmonary Fibrosis Treatment Market 2020 Global Industry Size, Segments, Share and Growth Factor Analysis Research Report 2025
August 20, 2020 |  marketwatch.com
Global Scleroderma Therapeutics Industry Report 2020-2025 - Growing Clinical Trials and Proven Efficacy of Immunosuppressants Will Drive Growth - ResearchAndMarkets.com
August 20, 2020 |  businesswire.com
Liminal BioSciences to Voluntarily Delist from the Toronto Stock Exchange
July 24, 2020 |  finance.yahoo.com
Liminal BioSciences Provides Guidance Update on Certain Expected Key Milestones For 2020
July 4, 2020 |  finance.yahoo.com
Liminal BioSciences Commences Collection of Convalescent Plasma from COVID-19 Recovered Donors
July 4, 2020 |  finance.yahoo.com
Liminal BioSciences Joins CoVIg Plasma Alliance to Contribute to Development of Potential New COVID-19 Therapy
July 4, 2020 |  finance.yahoo.com
See More Headlines

MarketRank™

Overall MarketRank™

0.46 out of 5 stars

Medical Sector

1679th out of 2,019 stocks

Pharmaceutical Preparations Industry

692nd out of 772 stocks

Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
$5.47
-0.20 (-3.58 %)
(As of 11/15/2019)
30 days | 90 days | 365 days | Advanced Chart

Receive PFSCF News and Ratings via Email

Sign-up to receive the latest news and ratings for PFSCF and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











ProMetic Life Sciences (OTCMKTS:PFSCF) Frequently Asked Questions

What stocks does MarketBeat like better than ProMetic Life Sciences?

Wall Street analysts have given ProMetic Life Sciences a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but ProMetic Life Sciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How has ProMetic Life Sciences' stock price been impacted by COVID-19 (Coronavirus)?

ProMetic Life Sciences' stock was trading at $5.4670 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, PFSCF stock has increased by 0.0% and is now trading at $5.4670.
View which stocks have been most impacted by COVID-19.

Who are ProMetic Life Sciences' key executives?

ProMetic Life Sciences' management team includes the following people:
  • Mr. Kenneth H. Galbraith, CEO & Director (Age 56)
  • Mr. Bruce Pritchard, COO & Interim CFO
  • Mr. Patrick Sartore, Chief Legal Officer & Corp. Sec.
  • Mr. Bruce Wendel, Chief Bus. Devel. Officer (Age 65)
  • Dr. John Moran, Chief Medical Officer (Age 73)

Who are some of ProMetic Life Sciences' key competitors?

Some companies that are related to ProMetic Life Sciences include Achaogen (AKAOQ), Cotinga Pharmaceuticals (COTQF), TetraLogic Pharmaceuticals (TLOG), Aoxing Pharmaceutical (AOXG), Propanc Biopharma (PPCB), Anthera Pharmaceuticals (ANTH), Sophiris Bio (SPHS), Aeolus Pharmaceuticals (AOLS), Adhera Therapeutics (ATRX), Spotlight Innovation (STLT), Sienna Biopharmaceuticals (SNNAQ), Praxsyn (PXYN), Skinvisible (SKVI), Argos Therapeutics (ARGSQ) and Therapix Biosciences (TRPXD).
View all of PFSCF's competitors.

What is ProMetic Life Sciences' stock symbol?

ProMetic Life Sciences trades on the OTCMKTS under the ticker symbol "PFSCF."

How do I buy shares of ProMetic Life Sciences?

Shares of PFSCF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ProMetic Life Sciences' stock price today?

One share of PFSCF stock can currently be purchased for approximately $5.47.

How much money does ProMetic Life Sciences make?

ProMetic Life Sciences has a market capitalization of $127.45 million and generates $36.55 million in revenue each year.

How many employees does ProMetic Life Sciences have?

ProMetic Life Sciences employs 487 workers across the globe.

What is ProMetic Life Sciences' official website?

The official website for ProMetic Life Sciences is www.prometic.com.

Where are ProMetic Life Sciences' headquarters?

ProMetic Life Sciences is headquartered at 440 Boulevard Armand-Frappier Suite 300, Laval A8, H7V 4B4.

How can I contact ProMetic Life Sciences?

ProMetic Life Sciences' mailing address is 440 Boulevard Armand-Frappier Suite 300, Laval A8, H7V 4B4. The company can be reached via phone at 1-450-781-0115 or via email at [email protected]


This page was last updated on 4/14/2021 by MarketBeat.com Staff

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.